|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus显示文摘The prognosis of patients with hepatocellular carcinoma (HCC) accompanied by portal vein tumor thrombus (PVTT) is generally poor if left untreated: a median survival time of 2.7-4.0 mo has been reported. Furthermore, while transcatheter arterial chemoembolization (TACE) has been shown to be safe in selected patients, the median survival time with this treatment is still only 3.8-9.5 mo. Systemic single-agent chemotherapy for HCC with PVTT has failed to improve the prognosis, and the response rates have been less than 20%. While regional chemotherapy with low-dose cisplatin and 5-fluorouracil or interferon and 5-fluorouracil via hepatic arterial infusion has increased the response rate, the median survival time has not exceeded 12 (range 4.5-11.8) mo. Combined treatment consisting of radiation for PVTT and TACE for liver tumor has achieved a high response rate, but the median survival rates have still been only 3.8-10.7 mo. With hepatic resection as monotherapy, the 5-year survival rate and median survival time were reportedly 4%-28.5% and 6-14 mo. The most promising results were reported for combined treatments consisting of hepatectomy and TACE, chemotherapy, or internal radiation. The reported 5-year survival rates and median survival times were 42% and 31 mo for TACE followed by hepatectomy; 36.3% and 22.1 mo for hepatectomy followed by hepatic arterial infusion chemotherapy; and 56% for chemotherapy or internal radiation followed by hepatectomy. | Masami Minagawa Masatoshi Makuuchi | 2006 | World Journal of Gastroenterology2006，12，47： | 74 |
| 2 | Current surgical treatment for bile duct cancer显示文摘Since extrahepatic bile duct cancer is difficult to diagnose and to cure,a safe and radical surgical strategy is needed.In this review,the modes of infiltration and spread of extrahepatic bile duct cancer and surgical strategy are discussed.Extended hemihepatectomy,with or without pancreatoduodenectomy(PD),plus extrahepatic bile duct resection and regional lymphadenectomy has recently been recognized as the standard curative treatment for hilar bile duct cancer.On the other hand,PD is the choice of treatment for middle and distal bile duct cancer.Major hepatectomy concomitant with PD(hepatopancreatoduodenectomy)has been applied to selected patients with widespread tumors.Preoperative biliary drainage(BD)followed by portal vein embolization(PVE)enables major hepatectomy in patients with hilar bile duct cancer without mortality.BD should be performed considering the surgical procedure,especially,in patients with separated intrahepatic bile ducts caused by hilar bile duct cancer.Right or left trisectoriectomy are indicated according to the tumor spread and biliary anatomy.As a result,extended radical resection offers a chance for cure of hilar bile duct cancer with improved resectability,curability,and a 5-year survival rate of 40%.A 5-year survival rate has ranged from 24% to 39% after PD for middle and distal bile duct cancer. | Yasuji Seyama Masatoshi Makuuchi | 2007 | World Journal of Gastroenterology2007，13，10： | 74 |
| 3 | Artificial and bioartificial liver support:A review of perfusion treatment for hepatic failure patients显示文摘Liver transplantation and blood purification therapy,including plasmapheresis,hemodiafiltration,and bioartificial liver support,are the available treatments for patients with severe hepatic failure.Bioartificial liver support,in which living liver tissue is used to support hepatic function,has been anticipated as an effective treatment for hepatic failure.The two mainstream systems developed for bioartificial liver support are extracorporeal whole liver perfusion(ECLP)and bioreactor systems.Comparing various types of bioartificial liver in view of function,safety,and operability,we concluded that the best efficacy can be provided by the ECLP system.Moreover,in our subsequent experiments comparing ECLP and apheresis therapy,ECLP offers more ammonia metabolism than HD and HF.In addition,ECLP can compensate amino acid imbalance and can secret bile.A controversial point with ECLP is the procedure is labor intensive,resulting in high costs.However,ECLP has the potential to reduce elevated serum ammonia levels of hepatic coma patients in a short duration.When these problems are solved,bioartificial liver support,especially ECLP,can be adopted as an option in ordinary clinical therapy to treat patients with hepatic failure. | Katsutoshi Naruse Masatoshi Makuuchi | 2007 | World Journal of Gastroenterology2007，13，10： | 23 |
| 4 | Precision surgery for primary liver cancer显示文摘Liver resection remains the best curative option for primary liver cancer, such as hepatocellular carcinoma(HCC) and intrahepatic cholangiocarcinoma.In particular, in liver resection for HCC, anatomical resection of the tumor-bearing segments is highly recommended to eradicate the intrahepatic metastases spreading through portal venous branches.Anatomical liver resection,including anatomical segmentectomy and subsegmentectomy using the dye-injection method, is technically demanding and requires experience for completion of a precise procedure.The recent development of imaging studies and new computer technologies has allowed for the preoperative design of the operative procedure, intraoperative navigation, and postoperative quality evaluation of the anatomical liver resection.Although these new technologies are related to the progress of artificial intelligence, the actual operative procedure is still performed as human-hand work.A precise anatomical liver resection still requires meticulous exposure of the boundary of hepatic venous tributaries with deep knowledge of liver anatomy and utilization of intraoperative ultrasonography. | Takeshi Takamoto Masatoshi Makuuchi | 2019 | Cancer Biology & Medicine2019，16，3： | 23 |
| 5 | Radiation therapy for portal venous invasion by hepatocellular carcinoma显示文摘AIM: To clarify the efficacy and safety of three-dimensional conformal radiotherapy (3-D CRT) for this disease and to specify patient subgroups suitable for this treatment.METHODS: Fifty-two patients with HCC received PVI-targeted radiation therapy from January 1995 through December 2003. Portal venous invasion (PVI) was found in the second or lower order branches of the portal vein in 6 patients, in the first branch in 24 patients and in the main trunk in 22 patients. Child classifications of liver function before radiation therapy were A, B, and C for 19, 24 and 2 patients, respectively. All patients received three-dimensional conformal radiotherapy with a total dose ranging from 39 to 60 Gy (57.0 Gy in average).RESULTS: Overall survival rates at 1, 2, 3, 4, and 5 years were 45.1%, 25.3%, 15.2%, 10.1%, and 5.1%, respectively. Univariate analysis revealed that Child status, the number of tumor foci, tumor type,transcatheter arterial embolization (TAE) after radiation therapy were statistically significant prognostic factors.Multivariate analysis showed that the number of tumor foci and TAE after radiation therapy were statistically significant.CONCLUSION: The results of this study strongly suggest the efficacy of 3-D CRT as treatment for PVI in HCC. 3-D CRT is recommended in combination with postradiation TAE for PVI of HCC with 5 tumor foci or less in the liver and with Child A liver function. | Keiichi Nakagawa Hideomi Yamashita Kenshiro Shiraishi Naoki Nakamura Masao Tago Hiroshi Igaki Yoshio Hosoi Shuichiro Shiina Masao Omata Masatoshi Makuuchi Kuni Ohtomo | 2005 | World Journal of Gastroenterology2005，11，46： | 14 |
| 6 | Clinical practice guidelines for hepatocellular carcinoma:the first evidence based guidelines from Japan显示文摘TO THE EDITORHepatocellular carcinoma (HCC) is one of the leadingcauses of cancer death in Japan, ranked 3^(rd) in males and5^(th) in females. Thanks to recent progress, there are severaldefinitive treatment modalities available for HCC, includ-ing surgery (liver resection and transplantation), ablationtherapy, and transarterial chemoembolization (TACE). Itis fortunate for both patients and doctors to have multipletreatment options, however, there have been very | Masatoshi Makuuchi Norihiro Kokudo | 2006 | World Journal of Gastroenterology2006，12，5： | 13 |
| 7 | KL-6 mucin expression in carcinoma of the ampulla of Vater: Association with cancer progression显示文摘AIM: To assess histochemical expression of KL-6 and its clinicopathological significance in carcinoma of the ampulla of Vater.METHODS: Ampullary carcinoma tissues were collected from 38 patients who underwent pancreatoduodenectomy or local resection. Tissues were subjected to immunohistochemical analysis using KL-6 antibody.RESULTS: Positive staining of ampullary carcinoma cells was observed in 26 (68.4%) cases. Staining was not found in the surrounding non-cancer regions of the ampullary tissues. Remarkable KL-6 expression was observed in invasive carcinoma cells in pancreatic and duodenal tissues and in metastatic carcinoma cells in lymph nodes. Positive KL-6 expression was related to lymph node metastasis (P = 0.020), pancreatic invasion (P = 0.016), duodenal invasion (P = 0.034), and advanced stage of TNM clinical classification (P = 0.010). Survival analysis showed that positive expression of KL-6 was related to a poorer prognosis (P = 0.029).CONCLUSION: The aberrant expression of KL-6 mucin is significantly related to unfavorable behaviors of carcinoma of the ampulla of Vater. | Wei Tang Yoshinori Inagaki Norihiro Kokudo Qian Guo Yasuji Seyama Munehiro Nakata Hiroshi Imamura Keiji Sano Yasuhiko Sugawara Masatoshi Makuuchi | 2005 | World Journal of Gastroenterology2005，11，35： | 10 |
| 8 | A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL/AASLD Recommendations?: An Observational Study of the HCC East-West Study Group显示文摘 | Guido Torzilli Jacques Belghiti Norihiro Kokudo Tadatoshi Takayama Lorenzo Capussotti Gennaro Nuzzo Jean-Nicolas Vauthey Michael A. Choti Eduardo De Santibanes Matteo Donadon Emanuela Morenghi Masatoshi Makuuchi | 2013 | Annals of Surgery2013，，5： | 7 |
| 9 | Neither Multiple Tumors Nor Portal Hypertension Are Surgical Contraindications for Hepatocellular Carcinoma显示文摘 | Takeaki Ishizawa Kiyoshi Hasegawa Taku Aoki Michiro Takahashi Yosuke Inoue Keiji Sano Hiroshi Imamura Yasuhiko Sugawara Norihiro Kokudo Masatoshi Makuuchi | 2008 | Gastroenterology2008，，7： | 7 |
| 10 | Prognostic Impact of Anatomic Resection for Hepatocellular Carcinoma显示文摘 | Kiyoshi Hasegawa Norihiro Kokudo Hiroshi Imamura Yutaka Matsuyama Taku Aoki Masami Minagawa Keiji Sano Yasuhiko Sugawara Tadatoshi Takayama Masatoshi Makuuchi | 2005 | Annals of Surgery2005，，2： | 6 |
| 11 | Prospective Cohort Study of Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma in 8510 Patients显示文摘 | Kenichi Takayasu Shigeki Arii Iwao Ikai Masao Omata Kiwamu Okita Takafumi Ichida Yutaka Matsuyama Yasuni Nakanuma Masamichi Kojiro Masatoshi Makuuchi Yoshio Yamaoka | 2006 | Gastroenterology2006，，2： | 5 |
| 12 | Inhibition of human gastric carcinoma cell growth by atofluding derivative N_3-o-toluyl-fluorouracil显示文摘AIM: To evaluate the growth inhibition efficacy of atofluding derivative N3-o -toluyl-fluorouracil (TFU) on human gastric carcinoma cell lines SGC-7901 and MKN-45. METHODS: Cell growth inhibition by TFU was measured by MTT and clonogenic assays without or with liver microsomal enzymes. Xenografts of cancer cells in nude mice were employed to study the anti-proliferative effects of TFU in vivo. RESULTS: TFU inhibited the growth of SGC-7901 and MKN-45 cells. However, the inhibitory effects of TFU on cell growth were not significant. The inhibition rates were enhanced in the presence of liver microsomal enzymes, ranging 4.73%-48.57% in SGC-7901 cells and 9.0%-62.02% in MKN-45 cells. In vivo, TFU delayed the growth of SGC-7901 and MKN-45 cells in nude mice. The inhibition rates were 40.49%, 63.24%, and 75.98% in SGC-7901 cells and 40.76%, 61.41%, and 82.07% in MKN-45 cells when the oral doses were 25, 50, and 100 mg/kg, respectively. TFU treatment was generally welltolerated by mice with less than 20% reduction in body weight. CONCLUSION: TFU inhibits the growth of human gastric carcinoma cells. The inhibition rates are increased in the presence of liver microsomal enzymes. The efficacy of TFU may be associated with the sustaining release of 5-fluorouracil (5-FU) mediated by the enzymes. | Jian Liu Wen-Fang Xu Shu-Xiang Cui Yong Zhou Yun-Xia Yuan Ming-Hui Chen Ruo-Han Wang Ruo-Yan Gai Masatoshi Makuuchi Wei Tang Xian-Jun Qu | 2006 | World Journal of Gastroenterology2006，12，42： | 5 |
| 13 | Microarray-based analysis for hepatocellular carcinoma: From gene expression profiling to new challenges显示文摘Accumulation of mutations and alterations in the expression of various genes result in carcinogenesis,and the development of microarray technology has enabled us to identify the comprehensive gene expression alterations in oncogenesis.Many studies have applied this technology for hepatocellular carcinoma(HCC),and identified a number of candidate genes useful as biomarkers in cancer staging,prediction of recurrence and prognosis,and treatment selection.Some of these target molecules have been used to develop new serum diagnostic markers and therapeutic targets against HCC to benefit patients.Previously,we compared gene expression profiling data with classification based on clinicopathological features,such as hepatitis viral infection or liver cancer progression.The next era of gene expression analysis will require systematic integration of expression profiles with other types of biological information,such as genomic locus,gene function,and sequence information.We have reported integration between expression profiles and locus information,which is effective in detecting structural genomic abnormalities,such as chromosomal gains and losses,in which we showed that gene expression profiles are subject to chromosomal bias.Furthermore,array-based comparative genomic hybridization analysis and allelic dosage analysis using genotyping arrays for HCC were also reviewed,with comparison of conventional methods. | Yutaka Midorikawa Masatoshi Makuuchi Wei Tang Hiroyuki Aburatani | 2007 | World Journal of Gastroenterology2007，13，10： | 5 |
| 14 | Clinical significance of subcellular localization of KL-6 mucin in primary colorectal adenocarcinoma and metastatic tissues显示文摘瞄准:估计在颜色代替 KL-6 粘蛋白和它的 clinicopathological 意义的细胞的本地化表面的癌以及变形淋巴节点和肝纸巾。方法:Colorectal 癌纸巾和肝纸巾从经历了 colorectomy 或肝切除术的 82 个病人被收集。纸巾受到免疫组织化学的分析使用 KL-6 抗体。结果:82 颜色表面的癌病人, 6 没显示出染色, 29 显示出仅仅在顶端的膜的积极染色,并且 47 显示出在环绕的膜或细胞质的积极染色。积极染色没在非癌的颜色被观察包围肿瘤纸巾的表面的上皮细胞。五年的幸存率在显示出比显示出仅仅在顶端的膜(85.7%) 的积极染色的那些和不显示出染色的那些(100%) 的在环绕的膜或细胞质(63.0%) 的积极染色的情况中是显著地更低的。在 KL-6 粘蛋白的细胞的本地化在环绕的膜或细胞质看了那 KL-6 本地化的 clinicopathological 因素和代用品之间的统计分析显著地与静脉的侵略的存在被联系( P = 0.0003 ),淋巴的侵略( P<0.0001 ),淋巴节点转移( P<0.0001 ),肝转移( P = 0.058 ),并且先进组织学的舞台( P<0.0001 )。积极染色在测试的所有变形损害以及在三原色被观察表面的癌纸巾。结论:潜水艇在颜色的 KL-6 的细胞的染色模式表面的腺癌可以是为象淋巴节点和肝转移那样的相反的行为,以及为病人的预后的重要指示物。 | Qian Guo Wei Tang Yoshinori Inagaki Yutaka Midorikawa Norihiro Kokudo Yasuhiko Sugawara MunehiroNakata Toshiro Konishi Hirokazu Nagawa Masatoshi Makuuchi | 2006 | World Journal of Gastroenterology2006，12，1： | 5 |
| 15 | Posthepatectomy liver failure: A definition and grading by the International Study Group of Liver Surgery (ISGLS)显示文摘 | Nuh N. Rahbari O. James Garden Robert Padbury Mark Brooke-Smith Michael Crawford Rene Adam Moritz Koch Masatoshi Makuuchi Ronald P. Dematteo Christopher Christophi Simon Banting Val Usatoff Masato Nagino Guy Maddern Thomas J. Hugh Jean-Nicolas Vauthey Pau | 2011 | Surgery2011，，5： | 4 |
| 16 | The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience显示文摘 | Pierre A. Clavien Jeffrey Barkun Michelle L. de Oliveira Jean Nicolas Vauthey Daniel Dindo Richard D. Schulick Eduardo de Santiba?es Juan Pekolj Ksenija Slankamenac Claudio Bassi Rolf Graf René Vonlanthen Robert Padbury John L. Cameron Masatoshi Makuuchi | 2009 | Annals of Surgery2009，，2： | 4 |
| 17 | Late-onset acute rejection after living donor liver transplantation显示文摘AIM: To investigate the incidence and risk factors of late-onset acute rejection (LAR) and to clarify the effectiveness of our immunosuppressive regime consisting of life-long administration of tacrolimus and steroids. METHODS: Adult living donor liver transplantation recipients (n = 204) who survived more than 6 mo after living donor liver transplantation were enrolled. Immunosuppression was achieved using tacrolimus and methylprednisolone. When adverse effects of tacrolimus were detected, the patient was switched to cyclosporine. Six months after transplantation, tacrolimus or cyclosporine was carefully maintained at a therapeutic level. The methylprednisolone dosage was maintained at 0.05 mg/kg per day by oral administration. Acute rejections that occurred more than 6 mo after the operation were defined as late-onset. The median follow- up period was 34 mo. RESULTS: LAR was observed in 15 cases (7%) and no chronic rejection was observed. The incidence of hyperlipidemia, chronic renal failure, new-onset post- transplantation diabetes, and deep fungal infection were 13%, 2%, 24%, and 17%, respectively. Conversion from tacrolimus to cyclosporine was required in 38 patients (19%). Multivariate analysis revealed that a cyclosporine- based regimen was significantly associated with LAR. CONCLUSION: Both LAR and drug-induced adverseevents happen at a low incidence, supporting the safety and efficacy of the present immunosuppression regimen for living donor liver transplantation. | Nobuhisa Akamatsu Yasuhiko Sugawara Sumihito Tamura Junichi Keneko Yuichi Matsui Kiyoshi Hasegawa Masatoshi Makuuchi | 2006 | World Journal of Gastroenterology2006，12，41： | 4 |
| 18 | Planning of anatomical liver segmentectomy and subsegmentectomy with 3-dimensional simulation software显示文摘 | Takeshi Takamoto Takuya Hashimoto Satoshi Ogata Kazuto Inoue Yoshikazu Maruyama Akiyuki Miyazaki Masatoshi Makuuchi | 2013 | The American Journal of Surgery2013，，： | 4 |
| 19 | Efficacy of mycofenolate mofetil for steroid-resistant acute rejection after living donor liver transplantation显示文摘瞄准:在类固醇作为抑制免疫力的药讨论 mycophenolate mofetil (MMF ) 的使用在肝移植以后的抵抗拒绝。方法:经历了生活施主肝移植(LDLT ) 的 260 个成年病人的临床的记录被考察。Tacrolimus 和甲基氢化尼松被用于主要免疫力的抑制。尖锐拒绝首先与类固醇被对待。当类固醇抵抗发生了时,病人与类固醇和 MMF 的联合被对待。Anti-T-cell 单音的同种细胞的抗体予不对在有 MMF 的联合的类固醇应答的病人被以。结果:90 的一个总数(35%) 病人们开发了尖锐拒绝。第一个事件的从移植的中部的间隔时间是 15 d。54 个病人是类固醇抵抗。44 个病人与 MMF 并且留下被对待 10 要求的 anti-T-cell 单音的同种细胞的抗体治疗。到长期的拒绝的前进在一个病人被观察。骨髓抑制和胃肠的症状是与 MMF 使用联系的最普通的副作用。机会主义的感染没有重要增加。结论:我们的结果证明 MMF 为在有在 LDLT 以后的尖锐拒绝的病人的营救治疗是一个有势力和安全抑制免疫力的代理人。 | Nobuhisa Akamatsu Yasuhiko Sugawara Sumihito Tamura Yuichi Matsui Junichi Kaneko Masatoshi Makuuchi | 2006 | World Journal of Gastroenterology2006，12，30： | 3 |
| 20 | Long-Term Outcome of Extended Hemihepatectomy for Hilar Bile Duct Cancer With No Mortality and High Survival Rate显示文摘 | Yasuji Seyama Keiichi Kubota Keiji Sano Tamaki Noie Tadatoshi Takayama Tomoo Kosuge Masatoshi Makuuchi | 2003 | Annals of Surgery2003，，1： | 3 |
您所在的机构暂未开通此部分的功能，请联系管理员